U.S. Competition Watchdog Decries Drug Deals

Law360, New York (January 17, 2007, 12:00 AM EST) -- As Congress hears arguments on so-called authorized generics, a new report by the Federal Trade Commission reveals what the antitrust watchdog calls a worrisome rise in cozy deals between generic and brand drug makers.

While the head of the world’s largest generic pharmaceutical manufacturers testified Wednesday before a senate committee in defense of rival company agreements, the Federal Trade Commission said the deals cheated consumers out of billions of dollars in savings on cheap drugs.

A study released Wednesday by the FTC shows the number of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.